Ampicillin Plus Ceftriaxone Is as Effective as Ampicillin Plus Gentamicin for Treating Enterococcus faecalis Infective Endocarditis
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The aim of this study was to compare the effectiveness of the ampicillin plus ceftriaxone (AC) and ampicillin plus gentamicin (AG) combinations for treating Enterococcus faecalis infective endocarditis (EFIE). METHODS: An observational, nonrandomized, comparative multicenter cohort study was conducted at 17 Spanish and 1 Italian hospitals. Consecutive adult patients diagnosed of EFIE were included. Outcome measurements were death during treatment and at 3 months of follow-up, adverse events requiring treatment withdrawal, treatment failure requiring a change of antimicrobials, and relapse. RESULTS: A larger percentage of AC-treated patients (n = 159) had previous chronic renal failure than AG-treated patients (n = 87) (33% vs 16%, P = .004), and AC patients had a higher incidence of cancer (18% vs 7%, P = .015), transplantation (6% vs 0%, P = .040), and healthcare-acquired infection (59% vs 40%, P = .006). Between AC and AG-treated EFIE patients, there were no differences in mortality while on antimicrobial treatment (22% vs 21%, P = .81) or at 3-month follow-up (8% vs 7%, P = .72), in treatment failure requiring a change in antimicrobials (1% vs 2%, P = .54), or in relapses (3% vs 4%, P = .67). However, interruption of antibiotic treatment due to adverse events was much more frequent in AG-treated patients than in those receiving AC (25% vs 1%, P < .001), mainly due to new renal failure (≥25% increase in baseline creatinine concentration; 23% vs 0%, P < .001). CONCLUSIONS: AC appears as effective as AG for treating EFIE patients and can be used with virtually no risk of renal failure and regardless of the high-level aminoglycoside resistance status of E. faecalis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the study by Fernández-Hidalgo et al, 191 26% of the 272 patients had high-level aminoglycoside-resistant strains of E faecalis.”
In the citing paper
“Sixth, in the larger study, there were no significant differences between ampicillin-ceftriaxone and ampicillin-gentamicin in the need for surgery, complications (except for fewer cases of renal failure in the ampicillin-ceftriaxone group), relapse, or mortality.”
In the citing paper
“Second, high-level aminoglycoside-resistant E faecalis IE treated with ampicillin-ceftriaxone therapy was present in 50% of the patients in the smaller study and 33% of patients in the larger study.”
In the citing paper
“Fourth, in the larger study, the median age was 70 years in both treatment groups; however, patients in the ampicillin-ceftriaxone group were generally sicker and had more comorbid conditions (eg, chronic renal failure [P=0.004],neoplasm [P=0.015], and nosocomial acquisition of infection [P=0.006]).”
In the citing paper
“First, these are the largest series of E faecalis IE reported to date, 43 patients in 1 study 190 and 272 in the other study.191”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027 · cited 1×
“Definitions IE was defined as definite or possible according to the modified Duke criteria [10].”
MethodMurdoch, D. R. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.603 · Cited by 2,362
Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009)
Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and by the International Society of Chemotherapy (ISC) for Infection and Cancer, Habib, G., Hoen, B., Tornos, P., Thuny, F., Prendergast, B., Vilacosta, I., Moreillon, P., de Jesus Antunes, M., Thilen, U., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp285 · Cited by 2,014
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Preeminence of Staphylococcus aureus in Infective Endocarditis: A 1-Year Population-Based Survey
Selton-Suty, C., Célard, M., Le Moing, V., Doco-Lecompte, T., Chirouze, C., Iung, B., Strady, C., Revest, M., Vandenesch, F., Bouvet, A., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis199 · Cited by 710
Intravascular catheter-related infections: advances in diagnosis, prevention, and management
Raad, I., Hanna, H., & Maki, D. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70235-9 · Cited by 525 · cited 1×
“Healthcare-associated IE [11] and catheter-related bacteremia [12] have been defined elsewhere.”
BackgroundContemporary Epidemiology and Prognosis of Health Care–Associated Infective Endocarditis
Fernández‐Hidalgo, N., Almirante, B., Tornos, P., Pigrau, C., Sambola, A., Igual, A., & Pahissa, A. (2008) · Clinical Infectious Diseases · doi:10.1086/592576 · Cited by 217
Self-citationGavaldà, J., Len, O., Miró, J. M., Muñoz, P., Montejo, M., Alarcón, A., de la Torre-Cisneros, J., Peña, C., Martínez-Lacasa, X., Sarria, C., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-8-200704170-00008 · Cited by 202 · cited 3×
“Since the publication of an observational, nonrandomized, multicenter clinical trial in 2007 [9], the ampicillin plus ceftriaxone (AC) combination has been recognized as a viable alternative for treating E.”
BackgroundSelf-citationMcDonald, J. R., Olaison, L., Anderson, D. J., Hoen, B., Miro, J. M., Eykyn, S., Abrutyn, E., Fowler, V. G., Habib, G., Selton-Suty, C., et al. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.02.020 · Cited by 170
Cited by
Items 301–346 of 346
Baires, F., Arias, E., Ramos, M. J. D., Burgos, C., López, G., Llompart, J. S., Radwanski, J., Tillman, T., Valerio, F., Sekhon, A. K., et al. (2023) · Preprints.org · doi:10.20944/preprints202311.1172.v1
Wichtige Antibiotikaindikationen und Krankheitsbilder unter ASB-Gesichtspunkten
Schulz-Stübner, S. (2024) · Springer eBooks · doi:10.1007/978-3-662-68836-6_11
Laethem, J. V. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.09.018
Antibiotische Therapie der Endokarditis
Schmidt-Hellerau, K., & Jung, N. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2351-1869
Endocarditis por Enterococcus faecalis inmunocompetente: reporte de caso
Bogotá, C. E. D. M. F. U. S., Angel, J. V. M., Benítez, L. V. R., Bogotá, C. E. D. M. F. U. S., & Pardo, S. S. (2024) · Horizonte Médico (Lima) · doi:10.24265/horizmed.2024.v24n4.14
Combined Antimicrobial Therapy for Infective Endocarditis
Gomez-Villegas, S. I., Miller, W. R., & Arias, C. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65839-6_16
Hernández, J., Ochoa, V., Dulcey, L., Gómez, J., Villamizar, D., Theran, J., Quitian, J., & Murcia, L. (2024) · Acta Bioclínica · doi:10.53766/acbio/2025.15.29.19
Wasselin, V., Budin‐Verneuil, A., Rincé, I., Desriac, F., Plouhinec, J., Boukerb, A. M., Hartke, A., Benachour, A., & Riboulet-Bisson, E. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf105
Fernández-Rubio, B., Docobo-Pérez, F., Hidalgo, L. H., López-Cortés, L. E., Márquez, R. L., Cabezas, J. M. L., López-Cortés, L. F., Mejías-Trueba, M., Gil, A. B. G., Gutiérrez‐Valencia, A., et al. (2025) · Antibiotics · doi:10.3390/antibiotics14050508
“Despite the intrinsic resistance of E . faecalis to ceftriaxone, when it is combined with ampicillin its presence is essential to enhance ampicillin activity, improving clinical results when combating difficult-to-treat infections such as IE [4,6,10].”
Enterococcal and Viridans Streptococcal Infections
McNeil, J. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00084-4
Villamarín, M., Fernández‐Hidalgo, N., & Escolà‐Vergé, L. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf164
Self-citationOldberg, K., & Rasmussen, M. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf320
GUIDANCE FOR IMPLEMENTING AN ANTIMICROBIAL STEWARDSHIP PROGRAM IN JAPAN
8学会合同抗微生物薬適正使用推進検討委員会 (2025) · Japanese Journal of Infection Prevention and Control · doi:10.4058/jsei.40.58
Yoshikawa, M., Nishimura, T., Misawa, K., Shimamura, R., Suzuki, K., Kashimura, S., Igarashi, Y., Enoki, Y., Taguchi, K., Hasegawa, N., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02012-25
Deconinck, L., & Duval, X. (2025) · EMC-Maladies infectieuses/Encyclopédie médico-chirurgicale. Maladies infectieuses · doi:10.1016/s1166-8598(25)47341-4
Ashrin, A., Hagenimana, C., Jacquier, H., Ourghanlian, C., Pressiat, C., Lepeule, R., Galy, A., Benhard, J., Reibel, F., Gallois, E., et al. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf426
Fraley, A. D., Eudy, J., & Anderson, D. T. (2025) · Therapeutics · doi:10.3390/therapeutics2040021
“Eventually, ampicillin plus ceftriaxone became a widely preferred treatment, as it was shown to be as effective and safer than an aminoglycoside combination regimen [7].”
Márquez, R. L. (2025) · Cirugía Cardiovascular · doi:10.1016/j.circv.2025.10.005
Detection of Virulence Genes Gel E and Asa1 in Enterococcus Faecalis Isolates
(2025) · Al-Azhar University Journal of medical and Virus Researches and Studies. · doi:10.21608/aujv.2025.470828
Sugiyama, K., Hirai, K., Suyama, Y., & Tsutsumi, M. (2024) · Figshare · doi:10.6084/m9.figshare.26749250
Apport de la modélisation mathématique en maladies infectieuses
Béraud, G. (. (2019) · LillOA (Université de Lille (University Of Lille))
Linee guida ESC 2023 per il trattamento dell’endocardite
Task force per il trattamento dell'endocardite della Società Europea di Cardiologie (ESC), European Association for Cardio-Thoracis Surgery (EACTS), & European Association of Nuclear Medicine (EANM) (2023) · Archive ouverte UNIGE (University of Geneva)
Raut, A. (2015) · Human Biology
Current Management of Serious Infections due to Vancomycin-resistant Enterococci
Gomez-Villegas, S. I., Wh, M., & Arias, C. A. (2026) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2025.12.004
Philip, M., Gravier-Dumonceau, R., Cosyns, B., Lancellotti, P., Donal, E., Prendergast, B., Erba, P. A., Popescu, B. A., Tribouilloy, C., Sengupta, S. P., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf784.2500
Profil épidémiologique de l'endocardite infectieuse au niveau du service de cardiologie CHU Tlemcen
Dadda, M. E., & Mankouri, M. A. (2024) · Dépôt Institutionnel de lUniversité de Tlemcen
Vijayakumar, K., Kannan, S., & Balakrishnan, J. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04829-2
“This results in a synergistic bactericidal effect (Fernández-Hidalgo et al. 2013).”
Aliyeva, S., Babayeva, N., Ruphullaev, I., Dadashova, G. M., Isgandarov, A., Jamilov, R., Azimova, M., & Hajizada, S. (2026) · Journal of Heart Disease and Therapy · doi:10.71295/jhdt.2026.03.1.05
Denizel Kaynaklı Aktinobakterilerin Sekonder Metabolitleri ve Bunların Biyoaktiviteleri
Can, Ö. (2024) · IYTE GCRIS Database (Izmir Institute of Technology)
Kornblum, D. S., Sharma, H., Kalia, R., Nair, A., Straughan, J., Pineda, R., Alomar, M., & Greene, J. (2026) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000001582
Aminosides : de la théorie à la pratique
Amoura, A., Tazi, A., Gauzit, R., & Canouï, É. (2026) · EMC-Maladies infectieuses/Encyclopédie médico-chirurgicale. Maladies infectieuses · doi:10.1016/s1166-8598(25)47343-8
Vicente, M. B. A., David, C., Cáceres-Lóriga, F. M., & Morais, H. (2026) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2026.18
“In elderly patients or those at risk of nephrotoxicity, the ampicillin– ceftriaxone combination has shown comparable clinical efficacy with a more favourable nephrotoxicity profile, as demonstrated by Fernández-Hidalgo et al. 9 .”
Alzain, A., Ahmed, M. S., Abdel-Raheem, S. M., Shukry, M., Albokhadaim, I., & Kandee, M. (2026) · Journal of Animal Health and Production · doi:10.17582/journal.jahp/2026/14.2.780.790
Shoman, A. M., & Radwan, A. A. (2026) · Infectious Diseases and Therapy · doi:10.1007/s40121-026-01361-0
When Less Is More: Volume Considerations in the Treatment of Enterococcus faecalis Endocarditis
El-Dalati, S. A., & Harris, W. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag199
“…improved tolerability compared with aminoglycoside-containing regimens, the 2015 American Heart Association and 2023 European Society of Cardiology (ESC) endocarditis guidelines recommend a combination of ampicillin and ceftriaxone for 6 weeks as first-line treat-ment of E faecalis IE [2, 3, 5].”
Zhang, F., Aziz, S., Dua, S., Grohol, B., & Ezeife, I. (2026) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytag387
Recurrent Prosthetic Valve Endocarditis With Aortomitral Curtain Destruction in an Elderly Patient
Cvetko, T.-T., Ćatić, J., Kursar, J., Šafradin, I., Lukšić, V. R., & Jurin, I. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.108370
Khan, R. Z. (2026) · Digital Commons - LIU Promoting Scholarship and Creative Work of LIU Students, Faculty, and Staff (Long Island University)
Li, Q., Huang, M., & Wang, P. (2026) · Biomedical Materials · doi:10.1088/1748-605x/ae859a
“Owing to its relatively high affinity for penicillin-binding proteins (PBPs, e.g. PBP5) in E. faecalis , ampicillin (Amp) in combination with gentamicin or ceftriaxone remains the first-line therapy for E. faecalis infections [9–12].”
Neves, S. D., Bourredjem, A., Chavanet, P., Ader, F., Bouiller, K., Lefèvre, B., Hentzien, M., Danion, F., Piroth, L., Binquet, C., et al. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.108987
Sugimoto, Y., Sasaki, R., Tominaga, M., Hirai, R., Mihara, T., Shimamura, R., Yoshikawa, M., Ikegami, S., Shimada, S., Tsubouchi, A., et al. (2026) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-026-05625-y
Mastroianni, C., Nenna, A., Fiorentino, M. F., Suàrez, S. M., Chello, M., & Loforte, A. (2019) · Institutional Research Information System University of Turin (University of Turin)
Acta Bioclínica Volúmen 15, N° 29: Enero - Junio 2025
- (2024) · Acta Bioclínica
Foster, R. A., Cluck, D. B., Rogers, D. J., White, B. P., Daut, L., Bland, C. M., Webb, B. J., Henao‐Martínez, A. F., & Chastain, D. B. (2026) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361261499816
Loja, J., Nascimento, R. F., Freitas, J. M., Ornelas, M., & Faria, T. (2026) · Cureus · doi:10.7759/cureus.119029
Metadata
- Authors
- Fernández-Hidalgo, N., Almirante, B., Gavaldà, J., Gurgui, M., Peña, C., de Alarcón, A., Ruiz, J., Vilacosta, I., Montejo, M., Vallejo, N., López-Medrano, F., Plata, A., López, J., Hidalgo-Tenorio, C., Gálvez, J., Sáez, C., Lomas, J. M., Falcone, M., de la Torre, J., Martínez-Lacasa, X., & Pahissa, A.
- Affiliations
- Vall d'Hebron Hospital Universitari (ES)
- Bellvitge University Hospital (ES)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Hospital Clínico San Carlos (ES)
- Hospital de Cruces (ES)
- Hospital Clínico Universitario de Valladolid (ES)
- Hospital Universitario Virgen de las Nieves (ES)
- Hospital Universitario de La Princesa (ES)
- Hospital Juan Ramón Jiménez (ES)
- Policlinico Umberto I (IT)
- University Hospital Mútua de Terrassa (ES)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-07
- Volume
- 56
- Issue
- 9
- Pages
- 1261-1268
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2137285136
- Semantic Scholar
- 9646599067b0e52124c95b08e69a38b3bd9e8a91
- Cited by
- 311
- References
- 22
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 25 · 2023: 23 · 2022: 16 · 2021: 19 · 2020: 26 · 2019: 35 · 2018: 21 · 2017: 21 · 2016: 23 · 2015: 26 · 2014: 16 · 2013: 19
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- Enterococcus faecalis, infective endocarditis, ampicillin, ceftriaxone, gentamicin, combination antibiotic therapy, aminoglycoside resistance, renal failure, treatment failure, relapse, mortality, adverse drug reactions
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Ampicillin, Anti-Bacterial Agents, Ceftriaxone, Drug Therapy, Combination, Endocarditis, Female, Gentamicins, Hospitals, Humans, Italy, Male, Middle Aged, Spain, Enterococcus faecalis, Cohort Studies, Treatment Outcome, Gram-Positive Bacterial Infections, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.